Jean-Yves Blay
让-伊夫·布莱
MD, PhD
Professor of Oncology; President & CEO, Centre Léon Bérard
👥Biography 个人简介
Jean-Yves Blay, MD, PhD is Professor of Oncology at Université Claude Bernard Lyon 1 and President & CEO of Centre Léon Bérard, the French National Cancer Institute comprehensive cancer center in Lyon. He is one of the world's preeminent authorities on sarcoma and gastrointestinal stromal tumors, having led pivotal clinical and translational research programs that transformed the systemic treatment of both diseases. His work spans molecular characterization of sarcoma subtypes, clinical trial leadership, and the construction of national and European reference networks for rare cancers. Dr. Blay founded and directed the French Sarcoma Reference Network (NETSARC) and was a principal architect of the European Conticanet network, establishing models for coordinated rare cancer care and research across Europe. He has been a lead investigator in numerous landmark trials of imatinib, sunitinib, regorafenib, and other targeted agents in GIST and sarcoma, and has authored over 600 peer-reviewed publications. He is a former president of the Connective Tissue Oncology Society (CTOS) and a recipient of major international honors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
French Sarcoma Network (NETSARC) Establishment
Founded and directed NETSARC, the French national reference network for sarcomas and GIST, demonstrating that centralized expert review of pathology and multidisciplinary management significantly improves outcomes for sarcoma patients and establishing a model adopted across Europe.
Imatinib and Targeted Therapy in GIST
Led landmark European BFR14 and related trials of imatinib in advanced GIST, contributing to the definition of optimal treatment duration, interrupted therapy, and the molecular basis of secondary resistance, informing clinical practice guidelines worldwide.
Regorafenib in Third-Line GIST
Principal investigator of the GRID phase III trial demonstrating that regorafenib significantly prolonged progression-free survival versus placebo in patients with advanced GIST after failure of imatinib and sunitinib, leading to regulatory approval.
European Sarcoma Network and Policy Leadership
Co-founded and led Conticanet (Connective Tissue Cancer Network) and served in multiple European network leadership roles, shaping EU policy on rare cancer care, biobanking, and multicenter trial infrastructure for mesenchymal tumors.
Representative Works 代表性著作
Regorafenib for patients with advanced gastrointestinal stromal tumor (GRID)
The Lancet (2013)
Phase III GRID trial demonstrating regorafenib significantly improved progression-free survival versus placebo in GIST after imatinib and sunitinib failure, establishing regorafenib as third-line standard of care.
Imatinib mesylate for advanced gastrointestinal stromal tumours
The Lancet (2002)
Pivotal European phase II trial demonstrating high response rates and disease control with imatinib in advanced GIST, establishing targeted therapy as the paradigm for molecularly driven solid tumor treatment.
NETSARC: a nationwide network for sarcoma management in France
European Journal of Cancer (2015)
Demonstration that multidisciplinary expert review through the NETSARC network leads to pathological reclassification in a significant proportion of sarcoma cases and improves patient management, supporting the European reference network model.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 让-伊夫·布莱 的研究动态
Follow Jean-Yves Blay's research updates
留下邮箱，当我们发布与 Jean-Yves Blay（Centre Léon Bérard, Université Claude Bernard Lyon 1）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment